On November 10, 2021 PharmaMar (MSE:PHM) reported that the abstract (number 464) titled "Lurbinectedin in combination with Atezolizumab for second line Extensive Stage Small Cell Lung Cancer patients" has been accepted for presentation at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting & Pre-Conference Programs (SITC 2021), that will take place on November 10th–14th, 2021, at the Walter E. Washington Convention Center in Washington, D.C. and virtually (Press release, PharmaMar, NOV 10, 2021, View Source [SID1234596673]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lead author, Santiago Ponce Aix, MD, Medical Oncology Specialist for Lung Cancer at HC Marbella International Hospital said:

"In recent years, treatment with immunotherapy has improved survival results in small cell lung cancer, as has lurbinectedin. On this occasion, at the American Society for Immunotherapy Congress, we presented the first data on the combination of both strategies in patients with small cell lung cancer, with very good activity data and a manageable toxicity profile."